Indications
Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.
Composition
- Active substance
- radium (223Ra) dichloride
- International name (INN)
- radium Ra223 dichloride
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xofigo
- Active substance
- radium (223Ra) dichloride
- ATC code
- V10XX03
- Group
- Various
- Therapeutic area
- Prostatic Neoplasms
- Marketing authorisation holder
- Bayer AG
- Status
- Authorised